Manufacturing News of Note—Pact Pharma snags Kite's Tim Moore; Catalent, Minerva hook up

stocks
(Pixabay)

> South San Francisco-based Pact Pharma has enticed Tim Moore from Gilead's Kite Pharma to serve as Pact's president and chief technical officer as it develops TCR-T cell therapies for the eradication of solid tumors. Release 

> Catalent and clinical-stage biotech Minerva Neurosciences have struck a deal for the CDMO to manufacture and package the finished dose form of roluperidone (MIN-101), Minerva’s investigational compound for the treatment of symptoms of schizophrenia. Release 

> Cellectis, a Swiss biotech working on immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), has reached an agreement for Lonza to handle clinical manufacturing. Release

On-Demand Webinar

De-Risking the Solid Form Landscape of an API

This presentation will discuss how predictable stability and solubility can minimize development timelines and cost. Attend to hear about two case studies exemplifying the importance of understanding the hydration space of an API and how hydrate formation may be avoided by development of a robust crystallization procedure.

> Novasep has launched Senefill, a unit dedicated to fill-and-finish aseptic commercial operations. It is in Seneffe, Belgium. Release

> Nanoform will conduct an evaluation of its nanoparticle technology across a range of AstraZeneca’s pharmaceutical products. Release

> CapsCanada, which makes vegetarian K-CAPS, is moving its headquarters to a facility in Dania Beach, Florida. Release 

 





 

Suggested Articles

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

Private equity player Ampersand Capital Partners is backing another CDMO, this one targeted at sterile injectables.

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.